Evidence map›Paper›PMID 24836949›Full record

ArticleBiomaterials2014

Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.

Xiaoyang Yang, Hongguang Liu, Chris K Sun, Arutselvan Natarajan, Xiang Hu, Xiaolin Wang, Mark Allegretta, Ronald D Guttmann, Sanjiv S Gambhir, Mei-Sze Chua and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 59 citations in OpenAlex.

  1. Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Review
  4. Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022
    Review
  15. Article
  16. Article
  17. Glypican-3 targeted delivery ofScientific reports · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xiaoyang YangAsian Liver Center, Department of Surgery, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Hongguang LiuMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, CA 94305, USA.
Chris K SunAsian Liver Center, Department of Surgery, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Arutselvan NatarajanMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, CA 94305, USA.
Xiang HuMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, CA 94305, USA.
Xiaolin WangAsian Liver Center, Department of Surgery, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Mark AllegrettaBioMosaics, Inc., Burlington, VT 05405, USA.
Ronald D GuttmannBioMosaics, Inc., Burlington, VT 05405, USA.
Sanjiv S GambhirMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, CA 94305, USA.
Mei-Sze ChuaAsian Liver Center, Department of Surgery, Stanford University, School of Medicine, Stanford, CA 94305, USA. Electronic address: mchua@stanford.edu.
Zhen ChengMolecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, CA 94305, USA. Electronic address: zcheng@stanford.edu.
Samuel K SoAsian Liver Center, Department of Surgery, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Stanford University · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

Imaging probes for early detection of hepatocellular carcinoma (HCC) are highly desired to overcome current diagnostic limitations which lead to poor prognosis. The membrane protein glypican-3 (GPC3) is a potential molecular target for early HCC detection as it is over-expressed in >50% of HCCs, and is associated with early hepatocarcinogenesis. We synthesized the positron emission tomography (PET) probe (89)Zr-DFO-1G12 by bioconjugating and radiolabeling the anti-GPC3 monoclonal antibody (clone 1G12) with (89)Zr, and evaluated its tumor-targeting capacity. In vitro, (89)Zr-DFO-1G12 was specifically taken up into GPC3-positive HCC cells only, but not in the GPC3-negative prostate cancer cell line (PC3). In vivo, (89)Zr-DFO-1G12 specifically accumulated in subcutaneous GPC3-positive HCC xenografts only, but not in PC3 xenografts. Importantly, (89)Zr-DFO-1G12 delineated orthotopic HCC xenografts from surrounding normal liver, with tumor/liver (T/L) ratios of 6.65 ± 1.33 for HepG2, and 4.29 ± 0.52 for Hep3B xenografts. It also delineated orthotopic xenografts derived from three GPC3-positive HCC patient specimens, with T/L ratios of 4.21 ± 0.64, 2.78 ± 0.26, and 2.31 ± 0.38 at 168 h p.i. Thus, (89)Zr-DFO-1G12 is a highly translatable probe for the specific and high contrast imaging of GPC3-positive HCCs, which may aid early detection of HCC to allow timely intervention.

Indexed as

Antibodies, MonoclonalGlypicansZirconiumAnimalsCarcinoma, HepatocellularCell Line, TumorDiagnostic ImagingFemaleHep G2 CellsHeterograftsHumansLiver NeoplasmsMaleMiceMice, NudeMice, SCIDAntibodies, MonoclonalGlypicansZirconium(89)ZrGlypican-3Hepatocellular carcinomaImmuno-PETMolecular imaging

Identifiers

PMID24836949
PMCPMC4363564
OpenAlexW2021048695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.